Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 904Lung Neoplasms 490Small Cell Lung Carcinoma 141Neoplasms 111Melanoma 107Neoplasm Metastasis 106Breast Neoplasms 99Colorectal Neoplasms 94Ovarian Neoplasms 76Carcinoma, Renal Cell 64Pancreatic Neoplasms 62Squamous Cell Carcinoma of Head and Neck 59Mesothelioma 53Stomach Neoplasms 51Head and Neck Neoplasms 47Triple Negative Breast Neoplasms 46Adenocarcinoma of Lung 46Esophageal Neoplasms 40Colonic Neoplasms 40Brain Neoplasms 40Sarcoma 38Mesothelioma, Malignant 38Prostatic Neoplasms 37Urinary Bladder Neoplasms 36Recurrence 30Carcinoma, Transitional Cell 28Uterine Cervical Neoplasms 25Endometrial Neoplasms 25Carcinoma, Hepatocellular 21Carcinoma, Squamous Cell 19

Interventions

zenocutuzumab 1enzalutamide 1Afatinib 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC Harboring NRG1 Fusion × Thoracic × Clear all
NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡